Janus Henderson Group PLC Increases Position in Sotera Health (NASDAQ:SHC)

Janus Henderson Group PLC boosted its stake in shares of Sotera Health (NASDAQ:SHC) by 43.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,892,868 shares of the company’s stock after purchasing an additional 4,525,056 shares during the quarter. Janus Henderson Group PLC owned about 0.05% of Sotera Health worth $178,865,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Sotera Health by 27.0% in the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock worth $145,863,000 after buying an additional 2,579,248 shares in the last quarter. P2 Capital Partners LLC lifted its holdings in shares of Sotera Health by 27.0% in the fourth quarter. P2 Capital Partners LLC now owns 2,350,000 shares of the company’s stock valued at $39,598,000 after purchasing an additional 500,000 shares in the last quarter. Irenic Capital Management LP grew its position in shares of Sotera Health by 103.2% in the fourth quarter. Irenic Capital Management LP now owns 2,233,195 shares of the company’s stock valued at $37,629,000 after purchasing an additional 1,134,039 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Sotera Health by 22.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,717 shares of the company’s stock worth $33,581,000 after purchasing an additional 363,628 shares in the last quarter. Finally, Untitled Investments LP raised its position in shares of Sotera Health by 47.0% during the 1st quarter. Untitled Investments LP now owns 1,409,091 shares of the company’s stock worth $16,923,000 after purchasing an additional 450,496 shares during the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SHC has been the topic of a number of analyst reports. Piper Sandler assumed coverage on Sotera Health in a report on Tuesday, May 21st. They set a “neutral” rating and a $13.00 target price on the stock. Citigroup upgraded shares of Sotera Health from a “neutral” rating to a “buy” rating and reduced their target price for the company from $18.00 to $16.00 in a report on Wednesday, April 3rd. Finally, Barclays cut their price objective on shares of Sotera Health from $19.00 to $14.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.92.

Sotera Health Trading Down 0.2 %

NASDAQ:SHC traded down $0.03 during mid-day trading on Tuesday, reaching $13.59. The company’s stock had a trading volume of 1,669,637 shares, compared to its average volume of 1,332,070. The company has a debt-to-equity ratio of 5.39, a current ratio of 3.20 and a quick ratio of 2.86. The stock has a market cap of $3.85 billion, a P/E ratio of 72.27 and a beta of 2.06. The company’s fifty day simple moving average is $12.00 and its two-hundred day simple moving average is $12.88. Sotera Health has a twelve month low of $10.71 and a twelve month high of $19.07.

Sotera Health (NASDAQ:SHC) last released its earnings results on Thursday, May 2nd. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.01). Sotera Health had a return on equity of 48.47% and a net margin of 5.09%. The company had revenue of $248.18 million during the quarter, compared to analyst estimates of $254.73 million. On average, equities analysts predict that Sotera Health will post 0.64 EPS for the current year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.